| scholarly article | Q13442814 |
| P356 | DOI | 10.1182/BLOOD-2015-09-671172 |
| P698 | PubMed publication ID | 26817954 |
| P50 | author | Nami Masubuchi | Q83121532 |
| P2093 | author name string | Norio Komatsu | |
| Akimichi Ohsaka | |||
| Yoshihisa Mizukami | |||
| Shin Kan | |||
| Shuichi Shirane | |||
| Yoko Edahiro | |||
| Yoshitaka Sunami | |||
| Marito Araki | |||
| Soji Morishita | |||
| Hiraku Takei | |||
| Yinjie Yang | |||
| Yumi Hironaka | |||
| P433 | issue | 10 | |
| P407 | language of work or name | English | Q1860 |
| P1104 | number of pages | 10 | |
| P304 | page(s) | 1307-1316 | |
| P577 | publication date | 2016-01-27 | |
| P1433 | published in | Blood | Q885070 |
| P1476 | title | Activation of the thrombopoietin receptor by mutant calreticulin in CALR-mutant myeloproliferative neoplasms | |
| P478 | volume | 127 |
| Q95492528 | Q95492528 |
| Q51683675 | Angiogenic factors are increased in circulating granulocytes and CD34+ cells of myeloproliferative neoplasms. |
| Q39321106 | Assessing the thrombotic risk of patients with essential thrombocythemia in the genomic era. |
| Q38844669 | Blast-phase myeloproliferative neoplasms: risk factors and treatment approaches |
| Q92518245 | Both sides now: losses and gains of mutant CALR |
| Q38378147 | CAL2 Immunohistochemical Staining Accurately Identifies CALR Mutations in Myeloproliferative Neoplasms |
| Q41845087 | CALR mutation characterization in myeloproliferative neoplasms |
| Q47347862 | CALR mutational status identifies different disease subtypes of essential thrombocythemia showing distinct expression profiles |
| Q92092554 | Calreticulin Ins5 and Del52 mutations impair unfolded protein and oxidative stress responses in K562 cells expressing CALR mutants |
| Q98177138 | Calreticulin and cancer |
| Q90702243 | Calreticulin haploinsufficiency augments stem cell activity and is required for onset of myeloproliferative neoplasms |
| Q42253829 | Calreticulin in Essential Thrombocythemia: StressINg OUT the Megakaryocyte Nucleus |
| Q41955541 | Calreticulin mutant mice develop essential thrombocythemia that is ameliorated by the JAK inhibitor ruxolitinib |
| Q38771057 | Calreticulin-mutant proteins induce megakaryocytic signaling to transform hematopoietic cells and undergo accelerated degradation and Golgi-mediated secretion |
| Q47317019 | Calreticulin: Challenges Posed by the Intrinsically Disordered Nature of Calreticulin to the Study of Its Function |
| Q57176814 | Cancer immune therapy for myeloid malignancies: present and future |
| Q40564541 | Circulating Calreticulin Is Increased in Myelofibrosis: Correlation with Interleukin-6 Plasma Levels, Bone Marrow Fibrosis, and Splenomegaly |
| Q31159627 | Clinicopathological differences exist between CALR- and JAK2-mutated myeloproliferative neoplasms despite a similar molecular landscape: data from targeted next-generation sequencing in the diagnostic laboratory. |
| Q49485576 | Defining the requirements for the pathogenic interaction between mutant calreticulin and MPL in MPN. |
| Q96640873 | Different impact of calreticulin mutations on human hematopoiesis in myeloproliferative neoplasms |
| Q47209528 | Driver mutations and prognosis in primary myelofibrosis: Mayo-Careggi MPN alliance study of 1,095 patients. |
| Q39414554 | Epigenetics in Myeloproliferative Neoplasms. |
| Q39306368 | Essential thrombocythemia: a review of the clinical features, diagnostic challenges, and treatment modalities in the era of molecular discovery |
| Q37397491 | Expression of CALR mutants causes mpl-dependent thrombocytosis in zebrafish |
| Q41684028 | Genetic Alterations of the Thrombopoietin/MPL/JAK2 Axis Impacting Megakaryopoiesis |
| Q87926953 | Guest Editorial: Understanding of MPN and MDS/MPN based on molecular pathogenesis and clinical aspects |
| Q48880601 | Histone Acetyltransferase p300/CREB-binding Protein-associated Factor (PCAF) Is Required for All-trans-retinoic Acid-induced Granulocytic Differentiation in Leukemia Cells. |
| Q89267519 | Homomultimerization of mutant calreticulin is a prerequisite for MPL binding and activation |
| Q90670796 | IL-6 stimulation of DNA replication is JAK1/2 mediated in cross-talk with hyperactivated ERK1/2 signaling |
| Q33779135 | Increased B cell activation is present in JAK2V617F-mutated, CALR-mutated and triple-negative essential thrombocythemia |
| Q33914515 | Induced Pluripotent Stem Cells: Global Research Trends |
| Q55638343 | Isolation of T cell receptors targeting recurrent neoantigens in hematological malignancies. |
| Q48109284 | JAK inhibitors for the treatment of myeloproliferative neoplasms and other disorders. |
| Q38684435 | JAK2 inhibitors for myeloproliferative neoplasms: what is next? |
| Q90037559 | JAK2V617F Megakaryocytes Promote Hematopoietic Stem/Progenitor Cell Expansion in Mice Through Thrombopoietin/MPL Signaling |
| Q63728935 | JAK2V617F but not CALR mutations confer increased molecular responses to interferon-α via JAK1/STAT1 activation |
| Q38775472 | Kinase signaling and targeted therapy for primary myelofibrosis |
| Q93023502 | Knock-in of murine Calr del52 induces essential thrombocythemia with slow-rising dominance in mice and reveals key role of Calr exon 9 in cardiac development |
| Q38798560 | Leptin-receptor-expressing bone marrow stromal cells are myofibroblasts in primary myelofibrosis |
| Q64100874 | Mice with Calr mutations homologous to human CALR mutations only exhibit mild thrombocytosis |
| Q38984558 | Molecular Pathogenesis and Clinical Significance of Driver Mutations in Primary Myelofibrosis: A Review |
| Q49834761 | Molecular Pathogenesis of Myeloproliferative Neoplasms: Influence of Age and Gender |
| Q37555785 | Molecular determinants of pathogenesis and clinical phenotype in myeloproliferative neoplasms |
| Q38978004 | Molecular testing for JAK2, MPL, and CALR in myeloproliferative neoplasms |
| Q58761454 | Multiple Roles of Glycans in Hematological Malignancies |
| Q94555011 | Mutant Calreticulin in the Myeloproliferative Neoplasms |
| Q90989171 | Mutant NRAS Q61K is responsible for MAPK pathway activation in the MARIMO cell line and renders these cells independent of the CALR-MPL-JAK2-STAT5 pathway |
| Q47111104 | Mutant calreticulin causes essential thrombocythemia |
| Q90338526 | Mutant calreticulin in myeloproliferative neoplasms |
| Q92965880 | Mutant calreticulin interacts with MPL in the secretion pathway for activation on the cell surface |
| Q59133186 | Mutant molecular chaperone activates cytokine receptor as a homomultimer |
| Q39027848 | Mutations in MPNs: prognostic implications, window to biology, and impact on treatment decisions |
| Q50072000 | Mutations in myeloproliferative neoplasms - their significance and clinical use. |
| Q39118859 | Myeloproliferative neoplasm stem cells. |
| Q53052368 | Novel germline mutations in the calreticulin gene: implications for the diagnosis of myeloproliferative neoplasms. |
| Q39457113 | Novel molecular mechanism of cellular transformation by a mutant molecular chaperone in myeloproliferative neoplasms. |
| Q38699339 | Overview of Transgenic Mouse Models of Myeloproliferative Neoplasms (MPNs). |
| Q93059368 | Overview of the Mutational Landscape in Primary Myelofibrosis and Advances in Novel Therapeutics |
| Q38717569 | Progenitor genotyping reveals a complex clonal architecture in a subset of CALR-mutated myeloproliferative neoplasms. |
| Q92209332 | Rare type 1-like and type 2-like calreticulin mutants induce similar myeloproliferative neoplasms as prevalent type 1 and 2 mutants in mice |
| Q51368335 | Recent advances in the genomics and therapy of BCR/ABL1-positive and -negative chronic myeloproliferative neoplasms. |
| Q39134073 | Regulation of Hematopoiesis and Hematological Disease by TGF-β Family Signaling Molecules |
| Q59799223 | Role of TGF-β1/miR-382-5p/SOD2 axis in the induction of oxidative stress in CD34+ cells from primary myelofibrosis |
| Q50092012 | Ruxolitinib vs best available therapy for ET intolerant or resistant to hydroxycarbamide. |
| Q49580473 | SOHO State-of-the-Art Update and Next Questions: MPN. |
| Q87992891 | Somatic mutations of calreticulin in myeloproliferative neoplasms |
| Q37638779 | Splanchnic vein thrombosis in myeloproliferative neoplasms: pathophysiology and molecular mechanisms of disease |
| Q99406585 | Surface-exposed and soluble calreticulin: conflicting biomarkers for cancer prognosis |
| Q92188227 | Targeted therapies for myeloproliferative neoplasms |
| Q93080041 | Targeting the CALR interactome in myeloproliferative neoplasms |
| Q49227755 | The Calreticulin control of human stress erythropoiesis is impaired by JAK2V617F in polycythemia vera |
| Q33433481 | The Calreticulin gene and myeloproliferative neoplasms |
| Q91762095 | The Expression of Myeloproliferative Neoplasm-Associated Calreticulin Variants Depends on the Functionality of ER-Associated Degradation |
| Q64085216 | The Role of New Technologies in Myeloproliferative Neoplasms |
| Q33440994 | The Thrombopoietin Receptor: Structural Basis of Traffic and Activation by Ligand, Mutations, Agonists, and Mutated Calreticulin |
| Q40392738 | Transduction-Transplantation Mouse Model of Myeloproliferative Neoplasm |
| Q88698331 | Tumor-associated calreticulin variants functionally compromise the peptide loading complex and impair its recruitment of MHC-I |
Search more.